Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Telix Pharmaceuticals Ltd. securities for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Telix Pharmaceuticals made materially false and misleading statements regarding its progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Telix securities during the class period [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in the field [4].
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX